BMC Medicine (Aug 2022)
Circulating exosomal mRNA signatures for the early diagnosis of clear cell renal cell carcinoma
- Xing He,
- Feng Tian,
- Fei Guo,
- Fangxing Zhang,
- Huiyong Zhang,
- Jin Ji,
- Lin Zhao,
- Jingyi He,
- Yutian Xiao,
- Longman Li,
- Chunmeng Wei,
- Caihong Huang,
- Yexin Li,
- Feng Zhang,
- Bo Yang,
- Huamao Ye,
- Fubo Wang
Affiliations
- Xing He
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Feng Tian
- Department of Urology, The Eighth People’s Hospital of Shanghai
- Fei Guo
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Fangxing Zhang
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Huiyong Zhang
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Jin Ji
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Lin Zhao
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Jingyi He
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Yutian Xiao
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Longman Li
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Chunmeng Wei
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Caihong Huang
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Yexin Li
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- Feng Zhang
- Department of Urology, The Eighth People’s Hospital of Shanghai
- Bo Yang
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Huamao Ye
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University)
- Fubo Wang
- Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University
- DOI
- https://doi.org/10.1186/s12916-022-02467-1
- Journal volume & issue
-
Vol. 20,
no. 1
pp. 1 – 13
Abstract
Highlights 1. Circulating exosomal RNA sequencing identified novel potential biomarkers of clear cell renal cell carcinoma (ccRCC). 2. The early diagnostic signature comprising KMT2D and PREX2 showed high accuracy in distinguishing ccRCCs from healthy individuals. 3. The differential diagnostic signature comprising CUL9, KMT2D, and PREX2 showed great performance in distinguishing ccRCCs from benign renal masses. 4. These signatures could be promising and noninvasive biomarkers for ccRCC detection.
Keywords
